Existing large scale molecular profiling analysis notes that PIK3CA H1047R and KRAS mutations appear to coexist in genitourinary cancers and breast cancers when noted, and are less prevalent concurrently in colorectal cancer [19]. Here, KRAS is linked to breast carcinoma.